Skip to main content
. 2016 May 17;7(27):41421–41431. doi: 10.18632/oncotarget.9404

Figure 5. Effect of apigenin on a nude mouse xenograft model.

Figure 5

Mice were treated with saline or apigenin (200 and 300 mg/kg) for 9 d. (A) Changes in the tumor volume of PLC/PRF/5 xenografts. Apigenin reduced tumor volume. (B) Apigenin treatment inhibited xenograft growth in a dose-dependent manner. (C) Body weights (g) of animals with PLC/PRF/5 xenografts. (D) The median survival time of the control xenograft groups was 34.0 ± 2.1 days. The median survival times for low-dose and high-dose apigenin xenograft groups were 39.0 ± 4.0 days and 41 ± 4.7 days, respectively. (E and F) The numbers of blood metastases in the tumor and tumors that shifted stoves decreased after apigenin treatment. Each experiment was performed in triplicate. The results are shown as the means of the three experiments, and the error bars represent standard deviation (*P < 0.05).